Cleveland Clinic researchers are first to test pomalidomide for refractory bleeding in hereditary hemorrhagic telangiectasia. Interim data signals reduced bleeding and reduced need for transfusions.
Cleveland Clinic hematologist Keith McCrae, MD, discusses the use of rituximab or splenectomy for patients with steroid-resistant idiopathic thrombocytopenic purpura in a recent ASH Clinical News article.
Cleveland Clinic research initiatives answer critical questions about the origin and treatment of blood disorders. These initiatives will be on display at the 56th Annual Meeting of the American Society of Hematology.
Specialized team focuses on research, reducing costs